{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:18:58Z","timestamp":1793333938046,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Fam Plann Reprod Health Care"],"accepted":{"date-parts":[[2016,3,16]]},"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are limited data to show the levels of prescribing of combined oral contraceptives (COCs) and other hormonal products containing estrogen\/progestogen combinations that may be outside the product licence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To determine the diagnosis\/indication recorded at the time of prescription of cyproterone acetate\/ethinylestradiol (CPA\/EE) and two COCs, levonorgestrel\/EE (LNG\/EE) and drospirenone\/EE (DRSP\/EE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and setting<\/jats:title>\n                  <jats:p>Retrospective study using a primary care database, The Health Improvement Network (THIN).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Women in THIN aged 12\u201349\u2005years prescribed CPA\/EE, LNG\/EE or DRSP\/EE in 2002\u20132010 were identified. Overall use of each product and proportion of new users each year were determined. Among new users, database codes were analysed to infer the reason for prescription.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The proportion of new users of each product in 2002 and 2010, respectively, were: LNG\/EE, 2.03% and 2.40%; CPA\/EE, 0.45% and 0.27%; and DRSP\/EE, 0.27% and 0.56%. Most new users prescribed CPA\/EE had a record of acne (51.0% and 79.2% in 2002 and 2010, respectively) or hirsutism (3.0% and 5.0% in 2002 and 2010, respectively); the proportion of new users with a record only for contraception decreased from 32.9% in 2002 to 8.6% in 2010. Among new users prescribed DRSP\/EE or LNG\/EE in 2010, 43.2% and 30.8% of women, respectively, did not have a record indicating use for contraception.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adherence to prescribing guidelines for CPA\/EE has improved over time. A substantial proportion of women using DRSP\/EE or LNG\/EE had records for hormone-responsive conditions only, suggesting that many women were prescribed these therapies for non-contraceptive use.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jfprhc-2015-101202","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T01:44:19Z","timestamp":1461203059000},"page":"247-254","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK"],"prefix":"10.1136","volume":"42","author":[{"given":"Luc\u00eda","family":"Cea-Soriano","sequence":"first","affiliation":[{"name":"Pharmacoepidemiologist, Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain"},{"name":"Department of Preventive Medicine and Public Health, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari-Ann","family":"Wallander","sequence":"additional","affiliation":[{"name":"Professor, Department of Public Health and Caring Science, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Alberto","family":"Garc\u00eda Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiologist, Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,4,20]]},"reference":[{"key":"2025090511383975000_42.4.247.1","unstructured":"Office for National Statistics. Contraception and Sexual Health, 2008\/09. http:\/\/www.ons.gov.uk\/ons\/rel\/lifestyles\/contraception-and-sexual-health\/2008-09\/2008-09.pdf [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.2","unstructured":"NHS Business Services Authority. Contraceptives (September 2010). http:\/\/www.nhsbsa.nhs.uk\/Documents\/Jul_-_Sep_10_Contraceptives.pdf [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.3","doi-asserted-by":"crossref","unstructured":"Arowojolu AO , Gallo MF , Lopez LM , et al . Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009;3:CD004425.","DOI":"10.1002\/14651858.CD004425.pub4"},{"key":"2025090511383975000_42.4.247.4","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmi019"},{"key":"2025090511383975000_42.4.247.5","doi-asserted-by":"publisher","DOI":"10.1783\/1471189054483780"},{"key":"2025090511383975000_42.4.247.6","unstructured":"Royal College of Obstetricians and Gynaecologists (RCOG). The Management of Menorrhagia in Secondary Care (Evidence Based Clinical Guidelines No. 5). London, UK: RCOG, 1999."},{"key":"2025090511383975000_42.4.247.7","unstructured":"Microgynon\u00ae 30. Summary of Product Characteristics. 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/1827\/SPC\/Microgynon+30\/ [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2008.12.003"},{"key":"2025090511383975000_42.4.247.9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1517\/14656566.9.13.2317","article-title":"Non-contraceptive benefits of oral contraceptives","volume":"9","author":"Huber","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"2025090511383975000_42.4.247.10","first-page":"392","article-title":"Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination","volume":"27","author":"Aydinlik","year":"1990","journal-title":"Clinical Trials Journal"},{"key":"2025090511383975000_42.4.247.11","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem379"},{"key":"2025090511383975000_42.4.247.12","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.109-4414"},{"key":"2025090511383975000_42.4.247.13","unstructured":"European Medicines Agency. Benefits of Diane 35 and its generics outweigh risks in certain patient groups. 2013. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Cyproterone-_and_ethinylestradiol-containing_medicines\/human_referral_prac_000017.jsp&mid=WC0b01ac05805c516f [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.14","unstructured":"CSD Medical Research UK. http:\/\/csdmruk.cegedim.com\/ [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.15","first-page":"173","article-title":"The history of the Read Codes: the inaugural James Read Memorial Lecture 2011","volume":"19","author":"Benson","year":"2011","journal-title":"Inform Prim Care"},{"key":"2025090511383975000_42.4.247.16","unstructured":"Dianette\u00ae. Summary of Product Characteristics. 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/1814\/SPC\/Dianette\/ [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031122"},{"key":"2025090511383975000_42.4.247.18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","article-title":"Epidemiology, diagnosis, and management of polycystic ovary syndrome","volume":"6","author":"Sirmans","year":"2013","journal-title":"Clin Epidemiol"},{"key":"2025090511383975000_42.4.247.19","unstructured":"Faculty of Family Planning & Reproductive Health Care. First Prescription of Combined Oral Contraception. 2007. http:\/\/www.fsrh.org\/pdfs\/FirstPrescCombOralContJan06.pdf [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.20","unstructured":"NHS Wandsworth Clinical Commissioning Group. Quick reference guide for combined oral contraceptives. http:\/\/www.wandsworthccg.nhs.uk\/aboutus\/Prescribing%20Guidelines\/Combined%20Oral%20Contraceptives%20Update%20-%202013%20Final.pdf [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0306-3356(21)00625-7","article-title":"The Oxford-Family Planning Association contraceptive study","volume":"11","author":"Vessey","year":"1984","journal-title":"Clin Obstet Gynaecol"},{"key":"2025090511383975000_42.4.247.22","first-page":"251","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"key":"2025090511383975000_42.4.247.23","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc-2011-100094"},{"key":"2025090511383975000_42.4.247.24","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg090"},{"key":"2025090511383975000_42.4.247.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.340"},{"key":"2025090511383975000_42.4.247.26","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.9.1021"},{"key":"2025090511383975000_42.4.247.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2437"},{"key":"2025090511383975000_42.4.247.28","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmr042"},{"key":"2025090511383975000_42.4.247.29","unstructured":"National Collaborating Centre for Women's and Children's Health. Heavy Menstrual Bleeding. 2007. http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG44NICEGuideline.pdf [accessed 7 December 2015]."},{"key":"2025090511383975000_42.4.247.30","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det457"},{"key":"2025090511383975000_42.4.247.31","first-page":"9\u2013","article-title":"Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE)","volume":"28","author":"Committe on Safety of Medicines","year":"2002","journal-title":"Current Problems in Pharmacovigilance"},{"key":"2025090511383975000_42.4.247.32","first-page":"4","article-title":"Cyproterone acetate with ethinylestradiol (co-cyprindiol): recommended duration of use","volume":"1","author":"Medicines and Healthcare Products Regulatory Agency","year":"2008","journal-title":"Drug Safety Update"}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jfprhc-2015-101202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:57:20Z","timestamp":1757098640000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/jfprhc-2015-101202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,10,6]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1136\/jfprhc-2015-101202"],"URL":"https:\/\/doi.org\/10.1136\/jfprhc-2015-101202","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"value":"1471-1893","type":"print"},{"value":"2045-2098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}